The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. AIMS. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. METHODS. We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20). We compared the baseline characteristics, changes of laboratory data and body weight. RESULTS. At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups. AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group. The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, P < 0.01). On the other hands, the body weight significantly increased in pioglitazone group and did not change in sitagliptin group. Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12-73.1, P = 0.04). CONCLUSIONS. Administration of liraglutide improved T2DM but also improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective study, liraglutide and pioglitazone, but not sitagliptin, decreased liver fibrosis index APRI (calculated as the aspartate aminotransferase (AST) to platelet count ratio), and the improvement was associated with weight loss and a marked reduction in AST and ALT levels [149].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · BMJ · doi:10.1136/bmj.39335.541782.ad · Cited by 10,766 · cited 1×
“This study was conducted according to STROBE statement [23].”
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406 · cited 2×
“The evaluation of liver fibrosis depended on calculation of aspartate aminotransferase (AST) to platelet counts ratio (APRI) index [22].”
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · cited 1×
“Improvement of insulin resistance and sensitivity has therapeutic effect in preventing the progression of NAFLD because the accumulation of triglycerides in hepatocytes is considered to be the first step in the current two-hit theory of the pathophysiological development of NAFLD [5].”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 12×
“Serum DPP-4 activity is reported to be significantly higher in NAFLD patients [17].”
InfluentialPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“The disorder is thought to be common because the incidence of its typical features, fatty liver disease, obesity, and type 2 DM, is increasing [25].”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Since in a randomized controlled trial intended for NAFLD patients, pioglitazone demonstrated alteration of liver inflammation but did not affect on improvement of liver fibrosis [6].”
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 2×
“Weight reduction via lifestyle intervention is generally recommended as an initial step in the management of NAFLD [27], and its effectiveness was proven in a randomized controlled trial [8].”
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 2×
“NAFLD is a liver disease that is characterized histologically by hepatic steatosis, lobular inflammation, and hepatocellular ballooning [24], and it was reported that at least 3% of the patients progressed to cirrhosis [3].”
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 2×
“Particularly, trials of glucose lowering agents such as metformin and pioglitazone have yielded promising results [18, 26].”
Research works printed but not linked: 2
- 10.1111/j.1572-0241.2003.07486.x · doi:10.1111/j.1572-0241.2003.07486.x · Paper page
- 10.1053/jhep.2003.50420 · doi:10.1053/jhep.2003.50420 · Paper page
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
“( 56 ) Co ho rt st ud y of n = 8 2 pa tie nt s w ith N AF LD , g iv en”
BackgroundFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Muzurović, E., Mikhailidis, D. P., & Mantzoros, C. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 336
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In this regard, Ohki et al. [97] observed a significant reduction in APRI in patients treated with liraglutide, similar to those treated with pioglitazone.”
BackgroundResultInfluentialNutrition, inflammation and liver-spleen axis
Barrea, L., Di Somma, C., Muscogiuri, G., Tarantino, G., Tenore, G. C., Orio, F., Colao, A., & Savastano, S. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1353479 · Cited by 263
“Thus, chronic low-grade systemic inflammation has been proposed as the link between Insulin Resistance (IR), T2DM, obesity, and cardiovascular disease (Shah and Brownlee 2016).”
MethodInfluentialFatty liver disease in diabetes mellitus.
Bhatt, H. B., & Smith, R. J. (2015) · PubMed · doi:10.3978/j.issn.2304-3881.2015.01.03 · Cited by 199
“Several clinical studies with sitagliptin in subjects with T2DM and NASH have shown decreases in alanine aminotransferase levels (38-40) and, in two studies, improved liver histology (38,40).”
BackgroundEguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Patel Chavez, C., Cusi, K., & Kadiyala, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 162
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 146
“In patients with NAFLD and NASH, it decreases liver fat contents and improves histological resolution and serum liver enzyme levels without worsening fibrosis [170,171].”
BackgroundSomm, E., Montandon, S. A., Loizides-Mangold, U., Gaïa, N., Lazarevic, V., De Vito, C., Perroud, E., Bochaton-Piallat, M.-L., Dibner, C., Schrenzel, J., et al. (2021) · Translational Research · doi:10.1016/j.trsl.2020.07.008 · Cited by 118
SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114
“In T2DM patients, administration of liraglutide, a GLP-1 analog, improved liver inflammation and altered liver fibrosis (28).”
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 107
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Carbone, L. J., Angus, P. W., & Yeomans, N. D. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13026 · Cited by 91
Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0180-0 · Cited by 86
“6%; N = 8); the most common comparators for liraglutide were: sitagliptin or any DPP-4i (N = 6) [32, 33, 35, 40, 56, 58], exenatide (N = 3) [33, 35, 50], glimepiride or any other SUs (N = 2) [30, 35], pioglitazone or other TZDs (N = 1) [35], and MET (N = 1) [35]; note: these numbers do not add up because some studies…”
BackgroundInfluentialAthyros, V. G., Pοlyzos, S. A., Kountouras, J., Katsiki, N., Anagnostis, P. G., Doumas, M. N., & Mantzoros, C. S. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164313 · Cited by 90
Wong, C., Lee, M. H., Yaow, C. Y. L., Chin, Y. H., Goh, X. L., Ng, C. H., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609110 · Cited by 86
“(29) Japan Retrospective Study Liraglutide GLP-1RA vs.”
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Lonardo, A., Ballestri, S., Targher, G., & Loria, P. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965143 · Cited by 86
Significance of circulatory DPP4 activity in metabolic diseases
Nargis, T., & Chakrabarti, P. (2018) · IUBMB Life · doi:10.1002/iub.1709 · Cited by 80
“Secretion of DPP4 from different cells in different metabolic diseases: DPP4 is shredded from (1) T lymphocytes in patients with T2DM via KLK5, (2) endothelial cells in cardiovascular disease, (3) adipocytes in obesity via MMPs, (4) smooth muscle in healthy individual via MMPs, and (5) hepatocytes in NAFLD patients.”
BackgroundBedi, O., Aggarwal, S., Trehanpati, N., Ramakrishna, G., & Krishan, P. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.10.004 · Cited by 85
“It is also reported that administration of liraglutide improved T2DM but also leading to improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.(86) Similarly, glucagon-like peptide 1 agonists and DPP-4 inhibitors show promising preliminary results in patients of NAFLD with diabe…”
BackgroundOhki, T., Isogawa, A., Toda, N., & Tagawa, K. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0383-1 · Cited by 83
“We previously demonstrated a reduction in liver inflammation and improvement of diabetes in NAFLD patients with T2DM after treatment with GLP-1 analogs and DPP-4 inhibitors [15].”
BackgroundSelf-citationMahjoubin‐Tehran, M., Vincentis, A. D., Mikhailidis, D. P., Atkin, S. L., Mantzoros, C. S., Jamialahmadi, T., & Sahebkar, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101049 · Cited by 73
“was shown that liraglutide may directly reduce live r fibrosis and steatosis in an i vivo study [26].”
BackgroundInfluentialNonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
Wattacheril, J. J., Issa, D., & Sanyal, A. J. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052545 · Cited by 72
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
Lv, X., Dong, Y., Hu, L., Lu, F., Zhou, C., & Qin, S. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.163 · Cited by 65
“A total of 6313 participants were studied, with a mean duration of 37 (12-144) weeks.”
BackgroundJanež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Scheen, A. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.902444 · Cited by 66
“Administration of liraglutide improved T2DM but also resulted in improvement of liver inflammation, alteration of liver fibrosis and reduction of body weight and compared favorably with sitagliptin and pioglitazone [101].”
ResultRezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8936865 · Cited by 65
Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., Bi, Y., & Zhu, D. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2713 · Cited by 63
“Another retrospective study suggested that ALT was significantly reduced by sitagliptin with a mean follow-up duration of 250 days [50].”
BackgroundConsensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment
Gangopadhyay, K., & Singh, P. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_512_16 · Cited by 65
“Liraglutide not only improved T2DM but also resulted in improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.[109] A meta-analysis of the “Liraglutide Effect and Action in Diabetes” program concluded that a 26-week therapy with liraglutide 1.”
BackgroundThe treatment of diabetes mellitus of patients with chronic liver disease
García‐Compeán, D., González, J. A., Lavalle-Gonzalez, F. J., González-Moreno, E. I., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2015) · Annals of Hepatology · doi:10.5604/16652681.1171746 · Cited by 64
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 60
The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Kosmalski, M., Ziółkowska, S., Czarny, P. L., Szemraj, J., & Pietras, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051375 · Cited by 62
“liraglutide is an independent factor affecting body weight reduction of more than 5% [186].”
BackgroundSuzuki, D., Toyoda, M., Kimura, M., Miyauchi, M., Yamamoto, N., Sato, H., Tanaka, E., Kuriyama, Y., Miyatake, H., Abe, M., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8961 · Cited by 61
“Recent studies have demonstrated the GLP-1 receptor expression in adipocytes (18) and liver cells (19).”
BackgroundRole of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61
Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2017) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
García‐Compeán, D., González, J. A., Lavalle-Gonzalez, F. J., González-Moreno, E. I., Villarreal‐Pérez, J. Z., & Maldonado-Garza, H. J. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3907-2 · Cited by 59
“Liraglutide was examined for the treatment of patients with NAFLD and DM and was shown to improve diabetic parameters, as well as reduce inflammation and liver fibrosis [91].”
BackgroundTreatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Portillo-Sanchez, P., & Cusi, K. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 56
“Liraglutide [69-75] GLP-1 receptor agonist ↓ ↓**^ Improved”
BackgroundCusi, K. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52
“Furthermore, Ohki et al.(22) reported that in Japanese patients with T2DM and NAFLD, sitagliptin did not modify either body weight or the aspartate to aminotransferase to platelet ratio index, which did decrease with pioglitazone or liraglutide (i.”
BackgroundInfluentialDhir, G., & Cusi, K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 53
Sayari, S., Neishaboori, H., & Jameshorani, M. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0006 · Cited by 55
“The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of patients with NAFLD.”
BackgroundInfluentialRizvi, A. A., Patti, A. M., Giglio, R. V., Nikolic, D., Amato, A., Al-Busaidi, N., Al-Rasadi, K., Soresi, M., Banach, M., Montalto, G., et al. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1067299 · Cited by 52
“We found an interesting trend in changes of lipid profile and anthropometric parameters, although not significant, that is in the line with the previous, larger studies which supported changes in these parameters after liraglutide therapy [11,34].”
ResultBajaj, H. S., Brown, R. E., Bhullar, L., Sohi, N., Kalra, S., & Aronson, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.001 · Cited by 50
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 48
Havranek, B., Loh, R., Torre, B., Redfield, R. L., & Halegoua-DeMarzio, D. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89408-z · Cited by 51
Spahis, S., Álvarez, F., Ahmed, N., Dubois, J., El-Jalbout, R., Paganelli, M., Grzywacz, K., DELVIN, E. E., Peretti, N., & Levy, E. H. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.03.025 · Cited by 51
Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., Deng, C., Yang, L., Kong, J., Chen, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102792 · Cited by 50
Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0157-y · Cited by 49
“Furthermore, a few data support a beneficial impact of liraglutide on liver inflammation markers in NAFLD patients with T2DM [67], in obese women with polycystic ovary syndrome and NAFLD [68], and in one T2DM patient with concomitant cryptogenic cirrhosis [69].”
BackgroundPotential of incretin-based therapies for non-alcoholic fatty liver disease
Samson, S. L., & Bajaj, M. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.005 · Cited by 47
“In a retrospective study of type 2 diabetes patients with NAFLD, as determined by ultrasonography and elevated ALT, treatment with liraglutide but not sitagliptin reduced ALT and the AST-to-platelet counts ratio index (APRI), suggested to reflect hepatic fibrosis (Ohki et al., 2012).”
BackgroundThe role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 42
Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs
Capuani, B., Pacifici, F., Della‐Morte, D., & Lauro, D. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00719 · Cited by 40
Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Blaslov, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7356 · Cited by 38
Zhang, N., Tao, J., Gao, L., Bi, Y., Li, P., Wang, H., Zhu, D., & Feng, W. (2020) · BioMed Research International · doi:10.1155/2020/2947549 · Cited by 31
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Sofogianni, A., Filippidis, A., Chrysavgis, L., Tziomalos, K., & Cholongitas, E. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.493 · Cited by 33
Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review
Olaywi, M., Bhatia, T., Anand, S., & Singhal, S. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60092-2 · Cited by 31
Njei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Ameyaw, P. A., Njei, L., & Boateng, S. (2024) · Cureus · doi:10.7759/cureus.71366 · Cited by 30
Park, K.-A., Jin, Z. H., Lee, J. Y., An, H. S., Choi, E. B., Kim, K. E., Shin, H. J., Jeong, E. A., Min, K. A., Shin, M. C., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020159 · Cited by 30
“In addition to decreasing glucose levels and stimulating weight loss, GLP-1R agonists have been used to treat T2DM accompanied by NAFLD [37,38].”
BackgroundResultGlucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
Chatterjee, S., Ghosal, S., & Chatterjee, S. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i18.441 · Cited by 30
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01431-2 · Cited by 27
“, ceramides, liraglutide treatment may be considered as one potential drug with activity against NAFLD [40, 41].”
BackgroundInfluentialTreating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
Kalogirou, M., & Sinakos, E. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i11.790 · Cited by 27
Wang, X., Zhao, B., Sun, H., You, H., & Qu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.866189 · Cited by 27
“However, body weight did not change in NAFLD patients with T2DM treated with sitagliptin (32).”
BackgroundChen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010158 · Cited by 27
“Liraglutide is a shorter-acting GLP-1 analog that acts on GLP-1 receptors present in hepatocytes [99].”
BackgroundSitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway
Shen, T., Xu, B., Lei, T., Chen, L., Zhang, C., & Ni, Z. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6554 · Cited by 26
“In a 5‑year retrospective review, participants with NAFLD had higher risks of impaired fasting glucose and type 2 diabetes mellitus (T2DM) compared with NAFLD‑free controls (2).”
InfluentialReview of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
Berković, M. C., Virović-Jukić, L., Bilić-Čurčić, I., & Mrzljak, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2740 · Cited by 25
Yen, F., Hsu, C., Wei, J. C., Hou, M., & Hwu, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.839456 · Cited by 23
“Liraglutide improved glycemic parameters and reduced body weight, inflammation, and liver fibrosis (74).”
BackgroundJung, C., & Mok, J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.18 · Cited by 23
Hepatitis C virus infection and diabetes
Das, G. C., & Bolusani, H. (2016) · Practical Diabetes · doi:10.1002/pdi.2017 · Cited by 22
Yilmaz, Y. N., Zeybel, M., Adalı, G., COŞAR, A. M., Sertesen, E., Gökcan, H., Bahçecıoğlu, H., Şahin, M., Kaya, C. T., Ergün, İ., et al. (2023) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0011 · Cited by 21
“[205,206] In the biopsy and randomized controlled trial of the liraglutide study (LEAN study), 39% of patients in the liraglutide arm and 9% of patients in the placebo arm experienced improvement in steatohepatitis.”
BackgroundPharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease
Lorbek, G., Urlep, Ž., & Rozman, D. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0047 · Cited by 21
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Papagianni, M., & Τζιόμαλος, Κ. (2015) · Europe PMC (PubMed Central) · Cited by 21
Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
Teshome, G., Ambachew, S., Fasil, A., & Abebe, M. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265631 · Cited by 20
Ajabnoor, G., Hashim, K. T., Alzahrani, M. M., Alsuheili, A. Z., Alharbi, A. F., Alhozali, A. M., Enani, S. M., Eldakhakhny, B. M., & Elsamanoudy, A. Z. (2023) · Diseases · doi:10.3390/diseases11010050 · Cited by 20
“However, the direct effect of GLP-1RAs on reducing liver enzyme levels is not fully understood, requiring further investigation [47].”
BackgroundXu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 20
Galatou, E., Mourelatou, E. A., Hatziantoniou, S., & Vizirianakis, I. S. (2022) · Antioxidants · doi:10.3390/antiox11061060 · Cited by 19
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
Gameil, M. A., Yousef, E. A. A. M., Marzouk, R. E., Emara, M., Abdelkader, A. H., & Salama, R. I. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01526-2 · Cited by 16
“Ohki et al. [41] explained the liraglutide-related improvement of dyslipidemia by enhanced satiety sensation and weight loss.”
Makri, E. S., Kita, M. D., Goulas, A., Papaioannidou, P., Efstathiadou, Z. A., Adamidou, F., & Pοlyzos, S. A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.030 · Cited by 15
Predictors of liver fibrosis progression in cohort of type 2 diabetes mellitus patients with MASLD
Alfadda, A. A., Alqutub, A. N., Sherbeeni, S. M., Aldosary, A. S., Alqahtani, S. A., Isnani, A. C., Gul, R., Khaleel, M. S., Al-Qasim, S., & Almaghamsi, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108910 · Cited by 13
Effects of Liraglutide and Vitamin E in Fructose-Induced Metabolic Syndrome in Rats
Geddawy, A., Hussian, M., Kamel, M. Y., Kamal, R., & Ibrahim, M. A. (2016) · Pharmacology · doi:10.1159/000449429 · Cited by 13
Yang, J. Y., Moon, A. M., Kim, H. H., Pate, V., Barritt, A. S., Crowley, M. J., Buse, J. B., Stürmer, T., & Alexopoulos, A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107706 · Cited by 12
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
“weight (−4 kg) and APRI index (a surrogate marker to evaluate the degree of liver fibrosis) [125].”
BackgroundWhich is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
Tsankof, A., Neokosmidis, G., Koureta, E., Veneti, S., Cholongitas, Ε., & Τζιόμαλος, Κ. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.984041 · Cited by 11
“Moreover, only liraglutide induced weight loss whereas semaglutide had no effect and weight increased in patients treated with pioglitazone (25).”
BackgroundPreinfalk, V., Kimmeswenger, I., Somoza, V., & Lieder, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30329 · Cited by 10
Berković, M. C., Režić, T., Bilić-Čurčić, I., & Mrzljak, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i20.6759 · Cited by 10
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
“Ohki et al., 2012 [65] Japan 26/36 26/20 Sitagliptin Pioglitazone Liraglutide daily 0.3 mg/first week, 0.6 mg/next week, and finally up to the limit dose of 0.9 mg if necessary 48 weeks for liraglutide US Body weight decreased from 81.1 to 78 kg. BMI from 30.1 to 28.6 kg/m2.”
BackgroundInfluentialThe role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Tsiampali, C., Papaioannidou, P., Goulas, A., & Pοlyzos, S. A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274536 · Cited by 10
“As expected, liraglutide decreased, pioglitazone increased, whereas sitagliptin had no effect on body weight [37].”
BackgroundIshikawa, T., Terai, N., Sato, R., Jimbo, R., Kobayashi, Y., Sato, T., Iwanaga, A., Sano, T., Yokoyama, J., & Honma, T. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3259-23 · Cited by 9
“Ohki et al. examined the effect of liraglutide, sitagliptin, and pioglitazone on NAFLD and reported that ALT levels were reduced by all agents, but weight loss was observed only with liraglutide (19).”
BackgroundNAFLD and cardiovascular disease
Martins, E., & Oliveira, A. B. F. D. (2018) · Porto Biomedical Journal · doi:10.1016/j.pbj.0000000000000002 · Cited by 9
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
Nysather, J. A., Kaya, E., Manka, P. P., Gudsoorkar, P. S., & Syn, W. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.04.001 · Cited by 8
Non Alkolik Yağlı Karaciğer Hastalığında Güncel Medikal Tedavi
Acay, A. (2015) · Kocatepe Tıp Dergisi · doi:10.18229/ktd.66765 · Cited by 8
Li, C., Zhao, L., Zhou, X., Wu, H., & Zhao, J. (2015) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-015-1433-2 · Cited by 8
The Real-World Costs of GLP-1 Receptor Agonist TreatmentPreprint
Wennberg, D. E., Coetzer, H., Marr, A. L., Margiotta, C., Hashmi, R., Kay, J., Vats, V., Hagen, S., Anatale‐Tardiff, L., Rao, S., et al. (2025) · medRxiv · doi:10.1101/2025.10.24.25338255 · Cited by 8
Peptide drugs application in metabolic diseases and discovery strategies
Bin, T. E. N. G., Junfeng, L. I., & Ren, P. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00063-8 · Cited by 7
Bołdys, A., Borówka, M., Bułdak, Ł., & Okopień, B. (2025) · Metabolites · doi:10.3390/metabo15080510 · Cited by 6
“However, two retrospective studies reported reductions in this index following liraglutide treatment [30,31].”
Metadata
- Authors
- Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K.
- Affiliations
- Mitsui Memorial Hospital (JP)
- The University of Tokyo (JP)
- Yamanashi Prefectural Hospital Organization (JP)
- Corresponding author
- Yoshida, Haruhiko
- Venue
- The Scientific World Journal
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 1537-744X (ISSN-L)
- PMC
- PMC3425807
- OpenAlex
- W2113064802
- Cited by
- 139
- References
- 29
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 14 · 2023: 11 · 2022: 10 · 2021: 15 · 2020: 15 · 2019: 11 · 2018: 11 · 2017: 6 · 2016: 14 · 2015: 10 · 2014: 9 · 2013: 3
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The Scientific World JOURNAL (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, non-alcoholic fatty liver disease, type 2 diabetes, sitagliptin, pioglitazone, weight loss, liver inflammation, ALT, HbA1c, glycemic control, GLP-1 receptor agonists
- MeSH terms
- Sitagliptin Phosphate, Liraglutide, Pioglitazone, Adult, Alanine Transaminase, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Evaluation, Drug Therapy, Combination, Fatty Liver, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Inflammation, Liver Cirrhosis, Male, Middle Aged, Platelet Count, Pyrazines, Retrospective Studies, Triazoles, Comorbidity, Multivariate Analysis, Logistic Models, Odds Ratio, Treatment Outcome, Thiazolidinediones, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.